Depomed — Merger or Acquisition (September 2015)
40 slides from Depomed's merger presentation, Sep 17, 2015
Slide 1: Filed pursuant to Rule 425
Filed pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filing by: Horizon Pharma public limited company Subject Company: Depomed, Inc. SEC File No. of Depomed, Inc.: 001-13111 This Rule 425 fil
Slide 2: Horizon Pharma plc Acquisition of Depomed, Inc.
Horizon Acquisition September For Non-Confidential Important Pharma 2015 of Information Depomed, plc Information Inc. About Benefits – Horizon the Proposed and Pharma Considerations Depomed plc Acquisition Please visit www.horizonanddepomed.com
Slide 3: Forward-Looking Statements
Forward-Looking This These facts. anticipated Depomed, that related disruption not the defend Securities applicable 2For potential Horizon pursue achieve full the presentation forward-looking to patents; businesses prescribing Non-Confidential future and from law risks ain the and transaction strate
Slide 4: Note Regarding Non-GAAP Financial Measures
Note and items included include Horizon The Depomed. GAAP Company adjusted gain be 3timing reasonably adjusted non-GAAP (loss) Regarding such and financial net Non-Confidential Pharma net inmay In on as other sales the income net addition, share-based derivative projected, be non-GAAP financial Use
Slide 5: Horizon's Offer to Acquire Depomed Is Compelling
165432 Both60% Horizon’s For Depomed Offer Pro Premium to forma Horizon’s Acquire and offer Horizon ownership commercialDepomed (1) Shareholders above Is Compelling Depomed’s relevant contribution inmodel Sizable Enhancedexpected scale operating has netcost potential and to increase taxinterests syn
Slide 6: Depomed Offer Delivers Compelling Premium
15Depomed rizon Fair Offer Depomed’s Adjusting Initial Exchange Proposal Price Implied 60% Pre-Announce 30-Day > NBI S&P Notes: Premium price VWAP Based $20.00 and Index 500 (VWAP) Pharma $29.25 delivers Public on Unless of based VWAP Premiums Premium Premium Reference(7/7)(7/21)(8/13) Non-Confident
Slide 7: Pro Forma Ownership Above Relevant Contribution
26Bloomberg PRo 25% Forma We Believe contribution Pro 40% 30% 32% August 0% 10% 20% w/Debt With performance using value, exclusively For Depomed Forma Ownership illustrative 37% 27% respect future settlement 13 Payoff Non-Confidential 2016E-2018E 27% Proposal Adjusted Depomed and in Adjusted sources
Slide 8: Horizon's Commercial Model Has Potential to Increase Net Sales
37Note: Horizon’s UCYNTA At % 15% +18% 25% 35% 150% 250% +306% 350% 05% -5% Week PENNSAID Shouldn’t Source: 1Change Week 2+3% +15% Commercial 3Re-launch from 4IMS Non-Confidential 12 5the Re-Launch TRx 6Launch Post 2% 7NPA Dedicated 8%9VIMOVO dates Model Re-Launch, Weekly. Change 10/ Re-Launch 11 Re
Slide 9: Horizon's Commercial Model Has Potential to Increase Net Sales
38Note: Horizon’s UCYNTA % 6/12/15 -50% 0% 50% 100% 150% 400% 450% 500% 550% DUEXIS In IR Source: Change the is Down Commercial Year-Over-Year Re-launch Period IMS 6/19/15 Non-Confidential PENNSAID Re-Launch 5%NPA Since Model Year-Over-Year Weekly 6/26/15 for Weekly. the NUCYNTA Results 2% NUCYNTA T
Slide 10: Horizon's Commercial Model Has Potential to Increase Net Sales
39(3) Horizon’s $60 HZNP 2H DUEXIS Source: (1) (2)Study: 2014 $62HZNP Net +42%Commercial seNon-Confidential Prescriptions 501,327 243,389 352,36 $157 IMS Excludes $211 234,515 1H PENNSAID Horizon 2015 NPA vs Net DEPO DEPO Sales PENNSAID2% sales estimate Model NUCYNTA, Monthly; 2H vs.DEPO Depomed 201
Slide 11: Horizon's Commercial Model Has Potential to Increase Net Sales
310 se Study: TRx DUEXIS Source: (1) (2) (3) (4) 2014 Horizon’s Prescriptions 656,857 501,327 630,493 HZNP 352,361 $146 2H Growth: +42% HZNP IMS Excludes $211 $157 1H PENNSAID Horizon 2015 NPA vs Net 1H DEPO $164 PENNSAID2% Non-Confidential Net FY2014actual sales Commercial DEPO 2015 Sales the Month
Slide 12: Example: PENNSAID 2% Transaction Highlights
311 Horizon’s NNSAID Transaction Nuvo $30.0 PENNSAID Millions) sales •$(and $10.0 listed acquisition, life 2014 Example Estimated Includes Acquired Added Immediate Maximizing $48mm Commercial Non-Confidential to lower (1) patents Research 2030 6allowed 1Q:15 of in $20.0 2% new patient based in(2) Ho
Slide 13: Example: VIMOVO Transaction Highlights
312 Harizon’s MOVO Transaction Acquired Immediate Maximizing $163mm Added Example AstraZeneca Includes Commercial Non-Confidential 4Demonstrates allowed new of in inand net Horizon Highlights November value 2013 Orange rapid sales patent Annual in Model through Growing growth Information Book the 20
Slide 14: Activating Pharmacy Benefit Lists to Drive Growth
313 Harizon’s MEWeek Activating % (4 80% DUEXIS—% DUEXIS—IMS 9,000 12,000 70% 10,000 60% 8,000 50% 40% 6,000 30% 4,000 20% 2,000 10% Effective 0% 2/14/14 8/1/14 Source: Exclusion of 0% 40% 30% 20% 10% 0Commercial Non-Confidential 0has 14,000 80% 7,000 6,000 5,000 3,000 Exclusion TRx 8/29/14 60% 50%
Slide 15: Horizon's Current Commercial Structure
(1) Harizon’s rrent 3(1) Pain 275 Sales /Depomed Neurology Source: Reps Commercial Commercial 24 Depomed Oncology 14 Non-ConfidentialSales Model Reps Corporate Structure Has–Potential Information Presentation Horizon to Increase Pharma dated plcNet September Sales 15, 2015.
Slide 16: Planned Commercial Structure
315 Harizon’s anned Pain 40 24 Oncology 14 Neurology 290 55 Commercial Rheumatology / Neurology Structure Sales Additional Clinical Reps Non-Confidential Sales Reps Science Sales 40 Model Provides Specialty Sales Reps Has atoLarger, Primary Information RepsMarket Potential More CareReps 325–Sales Ho
Slide 17: Sizable Operational and Tax Synergies Expected
4Sizable Operational We headcount “Given +$3 RBC, Note: Tax Horizon “DEPO HZNP Piper 16 Non-Confidential believe Synergies inJaffray, Permission July of NPV the should pays expects Expected course and 8, broader that Synergies (and a2015, July elimination corporate have the has combined opportunity
Slide 18: Enhanced Scale and Financial Flexibility
517 · We Horizon 2015E Sales Total EBITDA Average Interest Standalone September Market Represents $1,275mm Enhanced incremental Based Non-Confidential believe Debt Reps on Adj. Net Cap data Rate expects Depomed Borrowing (1) latest /15, Sales and (1) total Standalone amounts EBITDA senior (2) 2015E
Slide 19: Major Diversification of Net Sales
618 Major duced 4% 21% 7% 22% 8% 60% 11% NUCYNTA DUEXIS (1) 2% 3% 7% Diversification Currently Pro DEPO By Medicine forma, 15% 17% 10% Reliance %1% Source: VIMOVO of NUCYNTA no 1% GRALISE Net (1) single on Sales Non-Confidential of Horizon NUCYNTANet ACTIMMUNE medicine By Sales accounts CAMBIA Pharm
Slide 20: Longer Patent Life for Depomed Products
7Pharma Horizon’s rizon 50% Depomed Year 19 Horizon ?Longer Non-Confidential of 2022 Patent Horizon’s 2023 Terms Life 2024 2Q Products Extend Information 2015 2025 Well Net and 2026SalesDevelopment Beyond 2027 – Horizon Were 2028 2025 From 2029 Pharma CliffPrograms Medicines 2030 for plcDepomed 2031
Slide 21: Horizon's Initial IP Position for Products
Horizon’s 7H Initial No 1•approval listed 10, 2acquisition (excluding patents) 204orizon allowed OB Non-Confidential allowed Orange 2029 listable listed patents IPwith Aggressively Position market and Longer esomeprazole in Book and patents protection at patents 4Q 2Q 6 9•OB beginning Settled (OB) 2
Slide 22: Strengthening IP Position
Horizon’s 7w 2Initial extending perpetual 3know-how with protection 21 2032 hile U.S. OB Non-Confidential protection listed Strengthening IP patents Position Genentech to Longer to license patents 2022; 2032 2toU.S. IP Life FA Genentech 1IP Today •Information allowed patents Orphan Products for Orph
Slide 23: ACTIMMUNE Development Opportunity
Horizon’s 7D ACTIMMUNE Potential Friedreich’s life-shortening, with Prevalence 2,400 Research •(1,400 June Based FARA 22No Started epomed Non-Confidential no FDA 5,patients on as in 2015 FDA pivotal $500 Alliance the of patient In Longer approved of September Ataxia Our U.S.) approved ~3,700 in toul
Slide 24: Depomed Development Opportunity
Horizon’s 7D DEPOMED Milestone Both “…called as “We has -considering CEO Note: 23 Mark epomed INon-Confidential certainly mentioned, had medicines Mallinckrodt, Permission Trudeau been MNK-155, In Longer &aR&D Our royalty single been number evaluating is have View to not Life less Opportunity? Augus
Slide 25: Substantial Reduction in Leverage
824 Substantial $pomed’s Specialty Diversified Portfolio Patent Marketed Orphan Potential Pipeline ACTIMMUNE Significant M&A 4.6x (1) Horizon (2) Reduction inNon-Confidential millions Capacity(1) Terms terms Platform leverage ???? Business $500M Primary Products oncapacity: Product Represents Basedd
Slide 26: Published Analyst Reports
(1) Published 9W “Viewing durable Cowen, “We Stifel, “Per reduction RBC, “The Guggenheim, “Perception rather Leerink, As Source: Note: 25ith ofcontinue our Are debate 6/30/2015, Permission Depomed all Horizon diversification.” Wall Horizon Factset Depomed earlier were Overwhelmingly of the Analyst t
Slide 27: Depomed Investors Overwhelmingly Supportive
Published 9W 350% 300% 200% 250% 50% 45% 100% 113% 150% YTD 0% Source: (1) 26ith Non-Confidential Based 28% Are 1168% 333% 269% -Year Bloomberg. Overwhelmingly on Analyst Depomed’s 3-Year Reports Information unaffected and Supportive Investors – Horizon stockThat price Pharma WeofHave $20.64 plc Spo
Slide 28: Depomed Continues to Work Against Shareholders' Best Interests
Horizon Shareholders 10 Each Depomed’s The Premium Depomed 27 Non-Confidential amounts transaction attempt attempted based Continues has 14a Management were has yet filed was onbeen toconsidered 15-day to on explain not to Information engage April rebuffed Work announced continues credited VWAP and
Slide 29: Depomed Continues to Work Against Shareholders' Best Interests
Horizon Shareholders 10 Depomed’s That Depomed SECOND On and 28 Non-Confidential August July September the same THIRD 12th, Pharma Continues board TO day, 21st, 31st, shareholders Depomed’s LAST 15th, Depomed’s TO to Depomed believes delay LAST Depomed to possible Information Work any from that boar
Slide 30: Absent the Poison Pill, Special Meeting Could Have Happened
Depomed Absent Shareholders 10 without Special 29 Non-Confidential the meeting incurring Continues Poison request associated Pillto Information and Work could the delays Against have most – Horizon happened recent the Best Depomed Pharma July Interests 9th plc bylaw and of the amendments, special me
Slide 31: Actions in Furtherance of Our Efforts
•Actions Solicitation representing On –and Depomed Horizon 30 Request The Meeting Non-Confidential August September most Court to Pharma is recent Record bylaw ignored Two: One: Date able 3rd, commenced has approximately 8th, to Horizon Removal in Depomed Election set purchased changes Date call Hor
Slide 32: Expected Timeline of Events
Events #1 Amendments #2 Special Meeting Request September Sept Exchange and 31 commenced Removal Election Non-Confidential Proxy 8thExpected Meetings Special Request Sept #1offer Solicitation October of Meeting and Record 14th Directors made TBD Bylaw to Oct Nov Occur November #2 Information Date DE
Slide 33: What We Are Asking Depomed Shareholders To Do
(1) What –Meeting Tender 32Meeting WeWhite your Please One: are Two: Depomed Asking and Removal review Election Blue Non-Confidential Youshares the Proxy ofof toDepomed’s full the Do into Information Cards solicitation new Now –the slate to(1) offer directors callof Horizon materials in for director
Slide 34: Key Transaction Events
Key August September March May Horizon share transaction FIRST July Depomed pill to After 33 call Non-Confidential / Transaction 13th 27th amendment 6all-stock aMay OFFER months 31st special offers on July sets $29.25 announces files 15th $33.00 June 15-day request 7th all-stock Horizon revocation o
Slide 35: Summary Offer and Consideration
Summary Offer and Consideration combined Implied ·Ownership VWAPs August With performance using value, exclusively For Premium July 34 0.95x Exchange Offer Depomed 54% Non-Confidential illustrative 15-day 6,respect and future premium settlement expires 2015 exchange 12th 12, 31.7% based & based of c
Slide 36: Summary Exchange Offer Terms
–Summary Exchange Offer ·Conditions 35 Rescission Due Horizon Minimum Registration No Other Hearing Filed Non-Confidential restraints ·diligence Competition customary a preliminary shareholder of September on –tender of Key Filed the and and Poison legality Exchange listing conditions of no for law
Slide 37: Horizon's Offer to Acquire Depomed Is Compelling
165432 Both60% Horizon’s For Depomed Offer Pro Premium to forma Horizon’s Acquire and offer Horizon ownership commercialDepomed (1) Shareholders above Is Compelling Depomed’s relevant contribution 736 Sizable Enhanced Major expected Both Horizon’s 98 Published 10 Substantial Significant for (1) Depo
Slide 38: Additional Information
Additional This issued included the Solicitation of one shareholders other statement Pharma INVESTORS AMENDMENTS WITH ANY TRANSACTION DEPOMED, If submit proxy nominee VOTING CAREFULLY OWNERS PROXY CALLING Investors SEC’s or on 37 your proxies to Horizon Non-Confidential SEC. orcommunication Horizon
Slide 39: Certain Information Regarding Participants
Certain Horizon with seeking 2014, July April shareholders Additional other 38 Non-Confidential 27, the documents 16, which Information to 2015 requests Pharma 2015 nominate information was meetings. and and and/or filed filed tothe the call Regarding for Information Special with with Special You Th
Slide 40: Horizon Pharma plc Acquisition of Depomed, Inc.
Horizon Acquisition September For Please Non-Confidential Important visit Pharma 2015 www.horizonanddepomed.com of Information Depomed, plc Information Inc. About Benefits – Horizon the Proposed and Pharma Considerations Depomed plc Acquisition